Dapagliflozin & Kidney: Top 5 New Evidence Highlights in 2026

Chronic kidney disease (CKD) is among the most common and serious complications of type 2 diabetes (T2D), affecting nearly 32% of Indian patients with T2D and substantially increasing the risks of kidney failure, cardiovascular events, and premature mortality. ¹ In India, diabetic kidney disease (DKD) remains a leading cause of CKD, with both the Indian CKD Registry and the recent ICMR-INDIAB study highlighting diabetes as a major driver of impaired kidney function. ^{2, 3} Over the past decade, dapagliflozin has evolved from a glucose-lowering agent to an important kidney-protective therapy. More recently, a large JAMA Internal Medicine study (2026) reported lower risks of incident CKD and adverse kidney outcomes with SGLT2 inhibitors compared with GLP-1 receptor agonists, reinforcing their role in preventing and slowing diabetic kidney disease. ⁴

Following are the top 5 recent evidence highlights from this decade, as we review in 2026

1. SGLT2 Inhibitors including Dapagliflozin, Foundation of Renal Protection

A 2026 comparative effectiveness study using a target trial emulation design evaluated kidney outcomes among 36,279 SGLT2 inhibitor initiators and 18,782 GLP-1 receptor agonist initiators with metformin-treated T2D. Notably, dapagliflozin accounted for 35% of the SGLT2i cohort (12,812 patients), while 65% received empagliflozin. Over 5 years, the risk of chronic kidney disease (CKD)—defined as a ≥40% decline in eGFR, severe albuminuria, or kidney failure, was 19% lower with SGLT2 inhibitors than with GLP-1 receptor agonists (6.7% vs 8.2%; RR 0.81; 95% CI 0.76–0.87). SGLT2 inhibitor initiation was also associated with a 12% lower burden of acute kidney injury (AKI) (25.2 vs 28.7 events per 100 individuals; MCC ratio 0.88; 95% CI 0.83–0.93). Benefits were most pronounced among individuals without preexisting kidney disease, highlighting the potential of SGLT2 inhibitors for primary prevention of CKD in T2D. ⁴

2. Dapagliflozin Beyond eGFR—Newer Emerging Mechanistic Insights into Nephroprotection

The kidney benefits of dapagliflozin extend well beyond slowing eGFR decline. Emerging mechanistic evidence suggests that SGLT2 inhibition restores tubuloglomerular feedback, reducing intraglomerular pressure and hyperfiltration—key drivers of CKD progression. In addition, dapagliflozin may improve renal oxygenation by lowering tubular energy demand, while attenuating oxidative stress, inflammation, and fibrotic pathways implicated in chronic kidney injury. Experimental studies also indicate favorable effects on mitochondrial function and cellular metabolism, supporting preservation of nephron integrity. Importantly, many of these effects appear independent of glucose lowering, helping explain the consistent renal benefits observed across CKD populations with and without diabetes. Together, these findings have expanded the understanding of dapagliflozin from an eGFR-preserving therapy to a disease-modifying agent targeting multiple pathways involved in CKD progression. ⁵

3. Cardio-Renal Remodeling Benefits in CKD

Cardiovascular remodeling is an important biologic driver of CV morbidity and mortality in CKD, with left ventricular hypertrophy, myocardial fibrosis, and impaired ventricular compliance often preceding overt heart failure. Emerging evidence suggests dapagliflozin may favorably modify these pathophysiological disruptions. In the randomized, placebo-controlled DAPA-VO₂ CKD trial, 53 patients with CKD and preserved ejection fraction received dapagliflozin 10 mg daily or placebo for 12 weeks. Although peak oxygen consumption was unchanged, dapagliflozin reduced left ventricular (LV) mass by 11.3 g (P=0.018) and improved the LV mass-to-volume ratio by 0.08 g/mL (P=0.017), indicating reverse cardiac remodeling. ⁶ Mechanistically, SGLT2 inhibition has been associated with reduced myocardial fibrosis, ventricular stiffness, inflammation, and cardiac loading conditions, alongside improved myocardial energetics and cellular metabolism. ⁷ These findings suggest dapagliflozin may attenuate maladaptive cardiac remodeling while preserving kidney function in CKD. ^{6, 7}

4. Dapagliflozin – Consideration in Magnesium Homeostasis in Kidney Transplantation T2D Patients

Kidney transplantation is emerging as a new relevant consideration for dapagliflozin, particularly as hypomagnesemia affects 20–50% of kidney-transplant recipients and is linked to adverse cardiometabolic outcomes. ⁸ In a 2026 retrospective cohort study, 34 dapagliflozin-treated kidney transplant recipients were compared with 96 controls. After a median 8.1 months, dapagliflozin significantly increased serum magnesium (p=0.00018), corrected hypomagnesemia in 7 of 9 affected patients, and increased serum phosphate (p=0.026), while eGFR changes (p=.0001) reflected expected SGLT2 inhibitor hemodynamic effects. ⁸ In another randomized trial, dapagliflozin 10 mg daily for 38 weeks improved glycemic control, body weight, and insulin resistance in recipients with post-transplant diabetes mellitus without compromising eGFR or graft function. ⁹ Together, these findings support the metabolic, electrolyte, and renal safety benefits of dapagliflozin in selected kidney transplant recipients.

5. Dapagliflozin – Emerging Research in Non-Diabetic Chronic Kidney Disease (ND-CKD)

The renoprotective effects of dapagliflozin are increasingly being recognized beyond diabetic kidney disease. In the landmark DAPA-CKD trial, dapagliflozin 10 mg daily reduced major kidney outcomes in patients with CKD irrespective of diabetes status, including those with IgA nephropathy. ¹⁰ Reinforcing these findings, a 2026 real-world Indian case series evaluated six non-diabetic patients with glomerular disorders (five IgA nephropathy, one membranous nephropathy) treated with dapagliflozin 10 mg daily for six months. After an expected early eGFR dip, kidney function recovered from 38.8±9.2 to 44.8±9.8 mL/min/1.73 m² (p=0.0052), while proteinuria declined from 1.88±0.22 to 0.63±0.32 g/day (p=0.0002), with no reported adverse events. ¹¹ These findings support an expanding role for dapagliflozin as a disease-modifying therapy across diabetic and non-diabetic CKD populations.

Dapagliflozin - Clinical Practice Perspective: Where Do Current Guidelines Stand?

Guideline	eGFR Threshold	Key Practice Points
ADA Standards of Care 2026 12	Initiate if eGFR ≥20 mL/min/1.73 m²	SGLT2 inhibitors are recommended for kidney and cardiovascular protection irrespective of baseline HbA1c or need for additional glucose lowering.
KDIGO CKD Guideline 2024 13	Initiate if eGFR ≥20 mL/min/1.73 m²	Once initiated, it is reasonable to continue an SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m², unless it is not tolerated or kidney replacement therapy (KRT) is initiated. Also, It is reasonable to withhold SGLT2 inhibitors during prolonged fasting, surgery, or critical medical illness because of increased ketosis risk.

Importantly, the 2026 NICE update reflects the growing recognition that SGLT2 inhibitors such as dapagliflozin extend benefits beyond glycaemic control, helping slow CKD progression, reduce heart failure hospitalization and cardiovascular risk, while also supporting modest weight reduction.

Key Takeaways

Dapagliflozin has evolved from a glucose-lowering therapy to a foundational cardio-renal protective agent. Evidence from landmark trials, mechanistic studies, cardiac remodeling data, kidney transplant populations, and emerging real-world experience in non-diabetic CKD suggests benefits extending beyond glycemic control. Contemporary guidelines now support early use of SGLT2i, reinforcing dapagliflozin’s expanding role in slowing CKD progression and improving long-term renal and cardiovascular outcomes.